tripelennamine Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA PubChem repoDB

Active Ingredient History

NOW
  • Now
Tripelennamine (sold as Pyribenzamine by Novartis) is a drug that is used as an antipruritic and first-generation antihistamine. Histamine acting on H1-receptors produces vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Tripelennamine can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as newer antihistamines have replaced it.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

pbz | pbz-sr | pyribenzamin | pyribenzamine | pyrinamine base | tripelenamine | tripelennamin | tripelennamina | tripelennamine | tripélennamine | tripelennamine chloride | tripelennamine citrate | tripelennamine hcl | tripelennamine hydrochloride | tripelennaminum

Organizations (10)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (3)


 

Diaper Rash (approved 1948)

Sneezing (approved 1948)

Urticaria (approved 1948)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue